Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group. Zusätzlich bieten wir Ihnen in diesem Bereich Bildmaterial und Informationen zu unseren Veranstaltungen. Als Überblick unserer Forschungstätigkeiten stehen zudem unsere Annual Scientific Reports hier für Sie zum Download bereit.
04.07.2019 June 2019: Clinical results and biomarker analysis of the randomised phase II GeparNuevo study
We are pleased to inform you that the results of the randomised phase II GeparNievo (GBG 89) study that aimed to investigate durvalumab, a PD-L1 inhibitor, in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer (TNBC) has been published in the Annals of Oncology.
03.06.2019 May 2019: Long-term outcomes of the GeparSepto study
The long-term follow-up data of the phase III GeparSepto (GBG 69) study that aimed to compare weekly nab-paclitaxel with weekly sb-paclitaxel followed by epirubicin plus cyclophosphamide (EC) as neoadjuvant treatment in patients with primary breast cancer has been published in the Journal of Clinical Oncology.
27.05.2019 GBG Studien beim ASCO 2019: Ein Erfolg auf ganzer Linie
Auf dem ASCO-Kongress 2019 konnten wir einige Ergebnisse und neue Studienkonzepte der GBG vorestellen.
22.05.2019 Mutational landscape and therapy response in GeparSepto trial
Results of a next-generation sequencing (NGS) analysis conducted in the neoadjuvant GeparSepto study (GBG 69) have been published in the Clinical Cancer Research.
07.05.2019 AURORA: inital results presented
The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin.
02.05.2019 GBG Research at ESMO Breast Cancer 2019
Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.
10.04.2019 Results from E-VITA trial conducted with HER2-positive metastatic breast cancer patients
We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer has been published in the Anticancer Drugs.
01.03.2019 Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab
A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.
01.02.2019 Results of the GeparOcto trial
We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.
18.01.2019 Prof. Loibl unter den meist zitierten Wissenschaftlern in 2018
Prof. Dr. Sibylle Loibl gehört im Jahr 2018 mit Ihrer Arbeit im Bereich der Brustkrebsforschung zu den 1% der am meisten zitierten Wissenschaftlern.
17.12.2018 Results of an interim analysis from KATHERINE trial
We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.
16.12.2018 GBG-Jahrestreffen - Anmeldung möglich
Die Anmeldung zum GBG Jahrestreffen, sowie zum AGO-Meeting 2019 in Frankfurt ist ab sofort möglich.
30.11.2018 November 2018: Exploratory analysis on obese breast cancer patients from the PANTHER trial
Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment has been published in the Annals of Oncology.
29.11.2018 GBG Research at SABCS
Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.
15.11.2018 Save the Date: AGO-Mamma 2019
Das State-of-the-Art-Meeting 2019 der AGO Organkomission Mamma wird am 16. März 2019 in Frankfurt stattfinden.
05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial
The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.
15.10.2018 GBG Research at ESMO
Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.
11.10.2018 BIG newsletter no 9 is out
We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.
27.09.2018 Paper of the month: models for pCR
A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.
11.09.2018 BCC-Breast Cancer Conference 2019 in Vienna
The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna is less than seven months away.
